Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,530.52
    -994.19 (-1.93%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

EU agency backs AstraZeneca's MOVENTIG drug

Reuters - UK Focus

LONDON, Sept 26 (Reuters) - A drug for the treatment of opioid-induced constipation, MOVENTIG, from AstraZeneca (NYSE: AZN - news) , was recommended for approval by European regulators on Friday.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

The drug is used for treating opioid-induced constipation in adult patients who have had an inadequate response to laxatives.

AstraZeneca, which resisted a $118 billion takeover attempt by Pfizer (NYSE: PFE - news) in May, has already had several other drugs recommended by the European Medicines Agency on Thursday and Friday. (Reporting by Sarah Young; Editing by Neil Maidment)